Compare CFR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFR | BIO |
|---|---|---|
| Founded | 1868 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.7B |
| IPO Year | N/A | N/A |
| Metric | CFR | BIO |
|---|---|---|
| Price | $136.01 | $319.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $137.64 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 429.9K | 182.6K |
| Earning Date | 01-29-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | ★ 9.72 | N/A |
| Revenue | $2,141,575,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $14.17 | $1.62 |
| Revenue Next Year | $4.47 | $2.26 |
| P/E Ratio | $13.88 | ★ N/A |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $100.31 | $211.43 |
| 52 Week High | $146.44 | $373.69 |
| Indicator | CFR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 56.25 |
| Support Level | $132.93 | $316.57 |
| Resistance Level | $138.15 | $328.56 |
| Average True Range (ATR) | 2.52 | 7.80 |
| MACD | 0.42 | 1.69 |
| Stochastic Oscillator | 82.47 | 70.06 |
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.